Cervical lymphatic-to-vein bypass surgery to help clear brain waste in people with Alzheimer's and intracranial lymphatic circulation disorder
Official title: Effect of Cervical Lymphaticovenous Anastomosis and Cervical Lymph Node to Vein Anastomosis for the Patient With Intracranial Lymphatic Circulation Disorder
Run by Asan Medical Center · NCT07328386 · Data updated 2026-11-12
This procedure will try connecting neck lymphatic vessels or lymph nodes to veins to see if it helps clear amyloid and improve thinking in people with Alzheimer's disease who have intracranial lymphatic circulation disorder.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years to 100 Years |
| Sex | All |
| Enrollment | 114 (estimated) |
| Sponsor | Asan Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | February 20, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 9, 2026 |
| Trial ID | NCT07328386 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥19 years) with Alzheimer's disease confirmed by amyloid PET-CT or CSF testing, a GDS score of 3–5, diagnosed intracranial lymphatic circulation disorder, able to give informed consent, and willing to attend postoperative follow-up visits.
✕Probably not a fit
Patients with vascular dementia, other structural brain disease, uncontrolled severe systemic illness, prior neck surgery, or known hypersensitivity to indocyanine green are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, prospective interventional trial will enroll adults with Alzheimer's disease and intracranial lymphatic circulation disorder confirmed by amyloid PET-CT or CSF testing and a Global Deterioration Scale score of 3–5. Enrolled participants will undergo cervical lymphaticovenous anastomosis (LVA) or lymph node-to-vein anastomosis (LNVA) performed with supermicrosurgical techniques. Cognitive function will be measured at baseline and at 1, 3, 6, 9, 12, 18, and 24 months postoperatively following standard clinical care schedules. The trial aims to determine whether creating bypass routes for lymphatic drainage improves amyloid clearance and cognitive trajectories.
Why it matters
Potential benefit: If successful, these microsurgical bypasses could improve clearance of brain waste such as amyloid and slow or partially reverse cognitive decline in affected patients.
How similar studies have gone: Supermicrosurgical LVA and LNVA have shown clinical benefit for peripheral lymphedema, but applying these techniques to intracranial lymphatic dysfunction and cognition is a novel approach with limited human data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 19 years or older who are diagnosed with intracranial lymphatic circulation disorder based on neurological evaluation. * Global Deterioration Scale (GDS) score between 3 and 5 at screening. * Diagnosis of Alzheimer's disease confirmed by amyloid PET-CT or CSF amyloid testing, showing amyloid accumulation associated with lymphatic circulation disorder. * Able to provide written informed consent to participate in the study voluntarily. Exclusion Criteria: * Unable to undergo follow-up evaluation for at least 12 months after surgery. * Diagnosed with vascular dementia. * Presence of structural brain disease other than intracranial lymphatic circulation disorder. * Known hypersensitivity to indocyanine green (ICG). * Uncontrolled systemic medical conditions such as severe cardiopulmonary, renal, hepatic, or endocrine disorders. * History of previous neck surgery. * Refusal to participate or failure to provide informed consent. * Determined by the principal investigator to be unsuitable for participation due to any other clinical reason.
Where it's running
-
Asan Medical Center
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Jin geon Guen, MD, PhD
- Email: ione2bbest@naver.com
- Phone: +82230103600
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoustic Stimulation During Sleep for Alzheimer’s Disease
Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.
-
FAME: A Italian test to recognize famous faces and name them
This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.
-
NMS-01 safety test in people with mild to moderate Alzheimer's disease
This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.
-
Choose Myself (Before) Losing Myself
We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.
-
Lecanemab-irmb in Real-World Use for Alzheimer’s Disease
This study tests the safety of lecanemab-irmb in people with Alzheimer’s disease by looking at real-world brain-image changes and related events.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.